Forge Biologics provides end-to-end manufacturing services for adeno-associated virus (AAV) gene therapies, facilitating the transition from preclinical development to commercial production in a custom-designed cGMP facility. The company aims to increase patient access to effective gene therapies for rare genetic diseases by streamlining the manufacturing process.
Funding
$90M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing and manufacturing gene therapies, particularly adeno-associated virus (AAV) vectors, is complex and requires specialized expertise and facilities, creating a bottleneck for companies seeking to bring these therapies to market. This complexity can delay clinical trials and commercialization, hindering patient access to potentially life-saving treatments.
Solution
Forge Biologics offers comprehensive contract development and manufacturing organization (CDMO) services specifically for AAV gene therapies, streamlining the path from preclinical development to commercial production. Operating from a purpose-built, state-of-the-art cGMP facility, Forge provides end-to-end support, including process development, analytical testing, plasmid manufacturing, viral vector manufacturing, and fill-finish services. By offering a complete suite of services, Forge aims to accelerate gene therapy programs, reduce manufacturing costs, and increase patient access to these innovative treatments.
Target Audience
Forge Biologics serves biotechnology and pharmaceutical companies developing AAV gene therapies, ranging from early-stage startups to established organizations.
Features
- Custom-designed cGMP manufacturing facility ("The Hearth") exceeding 200,000 square feet
- Comprehensive AAV vector manufacturing services from preclinical to commercial scale
- Process development and optimization for scalable and robust manufacturing
- Analytical testing services to ensure product quality and regulatory compliance
- Plasmid manufacturing capabilities to support AAV vector production
- Fill-finish services for final product formulation and packaging